Ivan Kairatov is a seasoned biopharma expert whose career has been defined by a deep immersion in the research and development of next-generation medical technologies. With a focus on how innovation translates from the laboratory to the patient, he has become a leading voice in evaluating the viability of RNA-based therapies and genetic medicines. His perspective is particularly valuable now as the industry watches major players like Novartis execute multi-billion dollar strategies to dominate the landscape of rare neuromuscular disease treatments.
This discussion explores the recent clinical success of delpacibart braxlosiran, a breakthrough treatment for facioscapulohumeral muscular dystrophy. We examine the biological mechanism of antisense oligonucleotide conjugates and how they target specific genetic malfunctions to restore muscle function. Furthermore, the conversation delves into the significance of the Phase 1/2 trial data, the strategic implications of the massive acquisition of Avidity Biosciences, and the future pipeline of RNA drugs currently in development.
How does the mechanism of delpacibart braxlosiran represent a fundamental shift in how we approach muscle-wasting diseases like facioscapulohumeral muscular dystrophy?
The beauty of delpacibart braxlosiran, or del-brax, lies in its identity as an antisense oligonucleotide conjugate, which is a highly sophisticated way to deliver genetic medicine. In patients with this specific form of muscular dystrophy, a gene called DUX4 is expressed incorrectly, essentially poisoning the muscle fibers and leading to progressive weakness. By using this conjugate technology, the drug is designed to specifically target and silence that gene, effectively aiming to stop the damage at its source rather than just managing the outward symptoms. It represents a move toward precision medicine where we are not just treating the inflammation or the pain, but actually working to restore muscle function and slow the overall progression of the disease. This level of molecular targeting is what makes the platform so attractive to major pharmaceutical companies looking to solve previously untreatable genetic conditions.
Looking at the results from the Phase 1/2 study, what specific indicators suggest that this drug is making a tangible difference in the health of the participants?
The trial was a robust evaluation involving 90 patients, which is a significant number for such a rare condition, and it utilized three distinct cohorts to compare different doses against a placebo. What really stands out to me is the primary biomarker data, specifically the impact on KHDC1L, a biomarker regulated by the DUX4 gene, and the reduction in creatine kinase levels. Creatine kinase is a classic indicator of muscle damage, so seeing a decrease there suggests the drug is successfully protecting muscle tissue from further degradation. When you combine those laboratory findings with the earlier data showing that patients experienced increased mobility and physical strength, it creates a very compelling picture of “target engagement.” It’s one thing to see a change in a blood test, but it’s another to see a patient actually moving better, which is the ultimate goal of any neuromuscular therapy.
With Novartis committing $12 billion to this acquisition, how do you see the upcoming Phase 3 trials and the broader pipeline, including candidates like del-desiran and del-zota, shaping the company’s future?
The $12 billion deal for Avidity was a massive bet, and these trial results go a long way toward validating that investment for the Novartis leadership. As they move into Phase 3, the focus will shift to very concrete functional outcomes, such as the 10-meter walk and run test, which will provide the definitive proof needed for global regulatory agencies. However, the market is looking at more than just del-brax; there is a lot of anticipation surrounding del-desiran for myotonic dystrophy, with data expected in the second half of this year, and del-zota for Duchenne muscular dystrophy. If these other candidates in the pipeline show similar success, Novartis will have essentially cornered a significant portion of the RNA therapeutic market for rare diseases. The fact that their stock ticked up nearly 3% following the news shows that investors are beginning to see the potential for a high-value, long-term portfolio in this space.
What is your forecast for the future of antisense oligonucleotide conjugates in the broader landscape of genetic medicine?
I expect that we are entering an era where antisense oligonucleotide conjugates will lead to a wave of accelerated approvals for rare diseases that currently have no viable treatment options. The ability to achieve strong target engagement while reducing muscle damage biomarkers, as we saw in the del-brax trial, provides a blueprint for how we can tackle other genetic malfunctions. We will likely see more large-scale acquisitions as established pharmaceutical giants look to secure these innovative delivery platforms to bolster their own pipelines. Within the next few years, if the Phase 3 data remains consistent, these therapies could become the standard of care, moving us away from general treatments and toward a future of highly specialized, life-changing genetic interventions. The success of this deal suggests that the industry is finally finding the right balance between high-tech genetic research and practical clinical application.
